Maze Therapeutics, Inc. (MAZE) Institutional Ownership

Ownership Summary

Maze Therapeutics, Inc. (NASDAQ:MAZE) is held by 137 institutional investors per 13F filings through December 2025.

• They owned 104.9% of outstanding stock in December 2025, up from 93.8% the prior quarter.
• They increased total shares held in MAZE by 13.6% quarter over quarter, and investors in Maze Therapeutics stayed flat from a year ago.
• Activity in MAZE broke down as 98 buyers, 21 sellers, and 18 unchanged among 137 total holders.
• Institutional investors collectively held 48.02Mn shares in Maze Therapeutics as of December 2025, up by 5.75Mn shares quarter on quarter, and with no net change year over year.
• Frazier Life Sciences Management, L.P. is the top holder of Maze Therapeutics as of December 31, 2025, with 4.57Mn shares representing 9.98% of outstanding stock.
• Leading buyers of Maze Therapeutics shares for the quarter ending December 2025 were Janus Henderson Group Plc (2.39Mn), BlackRock, Inc. (971.14K), Bellevue Group AG (887.71K), Caligan Partners LP (550.19K), Squadron Capital Management LLC (490.0K).
• Top sellers of MAZE stock for the quarter ending December 2025 included TRV GP IV, LLC (1.6Mn), Matrix Capital Management Company, LP (1.17Mn), Alphabet Inc. (1.02Mn), Logos Global Management LP (277.3K), BALYASNY ASSET MANAGEMENT L.P. (234.51K).
• Business Quant data shows the 10 biggest positions in Maze Therapeutics as of December 2025 are held by Frazier Life Sciences Management, L.P. (4.57Mn), TRV GP IV, LLC (4.47Mn), Deep Track Capital, LP (4.25Mn), ARCH Venture Management, LLC (4.12Mn), Janus Henderson Group Plc (3.14Mn), BlackRock, Inc. (2.29Mn), a16z Capital Management, L.L.C. (1.7Mn), VANGUARD GROUP INC (1.7Mn), VR Adviser, LLC (1.55Mn), Alphabet Inc. (1.39Mn).